Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11739000 | 0.98 | TDP1 (0.57) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL9504003 | 0.84 | MTNR1A (0.47) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL11461555 | 0.84 | L3MBTL1 (0.50) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL9508056 | 0.83 | MTNR1A (0.46) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL9508062 | 0.83 | MTNR1A (0.46) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL9375103 | 0.82 | CYP1A2 (0.55) | TDP1CYP1A1CYP1B1KDM4EHPGD | |
| SCHEMBL21617919 | 0.81 | HSD17B10 (0.47) | TDP1KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL11107359 | 0.81 | TDP1 (0.51) | TDP1KDM4EHPGDALDH1A1GLA | |
| SCHEMBL14064624 | 0.80 | KDM4E (0.46) | CYP1A1CYP1B1KDM4EHPGDALDH1A1 | |
| SCHEMBL30490817 | 0.80 | KDM4E (0.46) | CYP1A1CYP1B1KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0380316-A2 | Preparation of alpha-methylareneacetic acids | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1990-08-01 | — | — | EP | claimed |
| EP-1439824-A2 | THREE-DIMENSIONAL SUSPENSION PRINTING OF DOSAGE FORMS | Therics, Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6710086-B1 | CHEMICALLY MODIFIED PHARMACOLOGICALLY ACTIVE AGENT IN CARRIER; REDUCE THE DAMAGE TO THE GASTROINTESTINAL TRACT | MEDINOX, INC. | 2004-03-23 | — | — | US | disclosed |
| WO-2003041690-A2 | THREE-DIMENSIONAL SUSPENSION PRINTING OF DOSAGE FORMS | THERICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | MEDINOX, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6407135-B1 | NITRIC OXIDE SCAVENGER COVALENTLY BONDED TO NON-STEROIDAL ANTIINFLAMMATORY AGENT OR OTHER DRUG; SIDE EFFECT REDUCTION | MEDINOX, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2001062085-A1 | PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6274627-B1 | ADMINISTERING COMPOUNDS SUCH AS N-METHYL-D-GLUCAMINE DITHIO-CARBAMATE DISULFIDE FOR IN VIVO REDUCTION OF FREE RADICAL LEVELS IN A SUBJECT | MEDINOX, INC. | 2001-08-14 | — | — | US | disclosed |
| WO-1996025152-A1 | PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES | NANOSYSTEMS L.L.C. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087840-A1 | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor | NOS1, PTGS1, NOS2 | TDP1 1133/4885CYP1A1 1740/4885CYP1B1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.